Get started
Silence Therapeutics Plc - American Depository ShareSS

Silence Therapeutics Plc - American Depository Share

4.32USDR
−0.18−4.00%
As of today at 13:57 GMT
USD
No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals Options

SLN fundamentals

Key facts

Market capitalization‪209.97 M‬USD
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−1.67USD
Founded1994
Employees (FY)116
CEOCraig Allen Tooman
Websitesilence-therapeutics.com
About

Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Ownership
‪‪47.22 M‬‬
Free Float shares
‪‪37.56 M‬‬ (79.54%)
Closely held shares
‪‪9.66 M‬‬ (20.46%)
Free Float shares
‪‪37.56 M‬‬ (79.54%)
Closely held shares
‪‪9.66 M‬‬ (20.46%)
Capital structure
Market cap
‪‪209.97 M‬‬
Debt
‪‪117.00 K‬‬
Cash & equivalents
‪‪147.33 M‬‬
Enterprise value
‪‪62.75 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪209.97 M‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
11.10x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
11.10x
Valuation ratios
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪11.00‬
‪22.00‬
‪33.00‬
‪44.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−2,815.00%‬
‪−2,115.00%‬
‪−1,415.00%‬
‪−715.00%‬
‪−15.00%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−48.00 M‬‬
‪‪−32.00 M‬‬
‪‪−16.00 M‬‬
‪0.00‬
‪‪16.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−45.00 M‬‬
‪‪−30.00 M‬‬
‪‪−15.00 M‬‬
‪0.00‬
‪‪15.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−36.00 M‬‬
‪‪−24.00 M‬‬
‪‪−12.00 M‬‬
‪0.00‬
‪‪12.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Ribonucleic Acid Therapeutics
By country
Period: 2024
United Kingdom
Germany

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪7.00 M‬‬
‪‪14.00 M‬‬
‪‪21.00 M‬‬
‪‪28.00 M‬‬
Actual
Estimate
Earnings
Next:May 14, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪−0.30‬
‪−0.20‬
‪−0.10‬
‪0.00‬
‪0.10‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

SLN does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−50.00 M‬‬
‪0.00‬
‪‪50.00 M‬‬
‪‪100.00 M‬‬
‪‪150.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪50.00 M‬‬
‪‪100.00 M‬‬
‪‪150.00 M‬‬
‪‪200.00 M‬‬
Assets
Liabilities